Company Profile

Corporate Philosophy

We will build a stable business to deliver optimal care to patients based on cutting-edge scince, with patient benefit first, around the world.

Action Guidelines

Work in good faith and enjoy!!
a. Patients, Science, Business
b. Act by thinking as part and as a whole
c. (and) "ARIGATOU"

Message from CEO


HuLA immune Co., Ltd. is a biotech from Osaka University. Our mission is to make patients smile by quickly delivering innovative medicines to in-order diseases such as autoimmune diseases and novel coronavirus infections. Our company was established in March 2017 as a result of the JST-START program by Professor Hisashi Arase (Immunochemistry) of the Institute of Microbial Diseases, Osaka University and the Immunology Frontier Research Center. Based on joint research with the Arase Lab., we will take on the challenge of solving medical issues involving immunity. In autoimmune diseases, we are developing innovative drugs / diagnostics that can cure antiphospholipid antibody syndrome (APS) and MPO-ANCA vasculitis and etc., which are unmet medical needs, by applying professor Arase's ""neo-self theory"". With regard to covid-19, we will apply technologies related to newly discovered infection-enhancing antibodies to critical markers and improved next-generation vaccines. We will achieve the development of innovative new drugs based on cutting-edge science, and we will be a company that can make patients smile and say ""thank you"". In this process, HuLA immune people will feel ""rewarding"" and be ""happy"", and as a whole we will be an excellent company that responds to the ""thoughts"" of their families, shareholders and investors, as well as society.

Yasuhiro Shindo, President and CEO

Company Profile

Trade Name HuLA immune Inc.
SENQ Kasumigaseki, 2F, NITTOCHI Building
1-4-1 Kasumigaseki, Chiyoda-Ku, Tokyo 100-0013, JAPAN
Capital, etc. * 602.96 million yen* (including capital and capital reserves)
Main Business Diagnostics/Therapeutics Business
of employees
and Advisor
Yasuhiro Shindo, Ph.D. President and CEO
Tadashi Mori, Ph.D Director
Yukoh Nakazaki, Ph.D. Director
Fumio Nishikaku, Ph.D. Director
Mikihiko Shinozaki, Ph.D. Director
Kazuhiro Akiyama Auditor
Hisashi Arase, Prof. Scientific Advisor
of Company
Mar 2017 Incorporated as a result of governmental startup assistance program ( JST-START )
Mar 2017 Entered into the joint study agreement for innovative medicines based on the theory which is originated from Dr.Arase with Osaka University Arase Laboratory
Jun 2017 Concluded a patent license agreement with Osaka University : Peptide Patent for the treatment of immune diseases.
Apr 2018 Concluded a comprehensive priority negotiation rights agreement with a mega pharmaceutical company.
Dec 2018 Capital injected by the Osaka Univ. Venture Capital Co., Ltd. and Mitsubishi UFJ Capital Co., Ltd. (series A)
Mar 2019 Concluded a contract with Osaka University to use diagnostic drug patents for the autoimmune disease "Antiphospholipid Antibody Syndrome (APS)" ("Diagnostic Drug Patent")
Sep 2019 Secured a large-scale research facility in the State-of-the-Art Infectious Diseases Research Building of The Institute of Microbial Diseases, Osaka University
Nov 2019 Entered into the joint research agreements with Meiji Seika Pharma Co.,Ltd. for 2 specific diseases.
May 2020 Capital injected by the Osaka Univ. Venture Capital Co., Ltd. and Mitsubishi UFJ Capital Co., Ltd.(series B)
Jun 2020 AMED-Birthday study by Kobe University, Tokyo University and Toyama University, etc. proved the usefulness of β2GPI ”neoself” antibody testing in infertility, published in Arthritis & Rheumatology.
Dec 2020 As a results of a joint research with Osaka Univ., we established an infection-enhancing antibody testing for COVID-19. Patent filed as an improved vaccine technology that does not induce infection-enhancing antibodies.
May 2021 We made a press release on the development of a test method for novel coronavirus infection-enhancing antibodies published in Cell magazine.

List of bases and access map

Tokyo Office SENQ Kasumigaseki, 1-4-1 Kasumigaseki, Chiyoda-ku,
Tokyo 100-0013, Japan
Research Institute for Microbial Disease of Osaka Univ. 3-1
Yamadaoka, Suita, Osaka 565-0871, Japan

Qualifications, Certifications and Certifications

Registration number of sanitary inspection laboratory:
Suita City Public Health Director Registration No. 3